Work

Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.e14535

Authors: A. Naing, P. LoRusso, G. Mills, D. Berry, L. Doyle, E. Rohren, A. Burger, H. Chen, N. L. Busaidy, R. Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, The Barbara Ann Karmanos Cancer Institute, National Cancer Institute

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2297690640

Cites:

Cited by: 1

Related to: 10